Eléments de l'association

	Peter Ellis	1
	Carcinoma, Non-Small-Cell Lung (drug therapy)	2
	Peter Ellis *Sauf* Carcinoma, Non-Small-Cell Lung (drug therapy)"	0
	Carcinoma, Non-Small-Cell Lung (drug therapy) *Sauf* Peter Ellis"	1
	Peter Ellis Et Carcinoma, Non-Small-Cell Lung (drug therapy)	1
	Peter Ellis Ou Carcinoma, Non-Small-Cell Lung (drug therapy)	2
	*Corpus*	751

List of bibliographic references

Number of relevant bibliographic references: 1.

Ident.	Authors (with country if any)	Title
000060	Charles Butts [Canada] ; Mark A. Socinski [États-Unis] ; Paul L. Mitchell [Australie] ; Nick Thatcher [Royaume-Uni] ; Libor Havel [République tchèque] ; Maciej Krzakowski [Pologne] ; Sergiusz Nawrocki [Pologne] ; Tudor-Eliade Ciuleanu [Roumanie] ; Lionel Bosquée [Belgique] ; José Manuel Trigo [Espagne] ; Alexander Spira [États-Unis] ; Lise Tremblay [Canada] ; Jan Nyman [Suède] ; Rodryg Ramlau [Pologne] ; Gun Wickart-Johansson [Suède] ; Peter Ellis [Canada] ; Oleg Gladkov [Russie] ; José Rodrigues Pereira [Brésil] ; Wilfried Ernst Erich Eberhardt [Allemagne] ; Christoph Helwig [Allemagne] ; Andreas Schröder [Allemagne] ; Frances A. Shepherd [Canada]	Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.

Wicri

This area was generated with Dilib version V0.6.38.
Data generation: Fri Jun 18 17:37:45 2021. Site generation: Fri Jun 18 18:15:47 2021